{"id":2899,"text":"This study evaluated the effects of Newbouldia laevis and Cassia abbreviata extracts on CYP450 enzyme activity.","label":[[36,53,"Herb name"],[58,75,"Herb name"],[76,84,"Extraction process"],[88,94,"Target"]],"Comments":[]}
{"id":2900,"text":"Recombinant CYP450 enzyme and fluorogenic substrates were used for evaluating inhibition, allowing the assessment of herb–drug interactions (HDI).","label":[[12,18,"Target"]],"Comments":[]}
{"id":2901,"text":"Phytochemical fingerprinting was performed using UPLC-MS.","label":[],"Comments":[]}
{"id":2902,"text":"The herbal extracts were risk ranked for HDI based on the IC African populations have used herbal medicines for many centuries.","label":[[11,19,"Extraction process"],[58,60,"Parameter"],[61,68,"Ethnic group"]],"Comments":[]}
{"id":2903,"text":"Knowledge regarding specific plants and parts of these plants and their function in disease treatment is traditionally passed on from one generation to the next.","label":[],"Comments":[]}
{"id":2904,"text":"With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].","label":[],"Comments":[]}
{"id":2905,"text":"It has been demonstrated over the years that herbal remedies possess great therapeutic potential in managing and treating a number of diseases including malaria, hypertension, HIV\/AIDS, and cancer.","label":[[153,160,"Pathology"],[162,174,"Pathology"],[176,179,"Pathology"],[180,184,"Pathology"],[190,196,"Pathology"]],"Comments":[]}
{"id":2906,"text":"The use of herbal remedies is especially relevant in developing countries [3,4] due to their affordability and accessibility compared to orthodox health interventions.","label":[],"Comments":[]}
{"id":2907,"text":"Evidence available shows that there are potential interactions between drugs and herbs, some with fatal clinical outcomes [5,6,7].","label":[],"Comments":[]}
{"id":2908,"text":"Despite these fatal herb-drug clinical outcomes, there is still limited information on monitoring herb–drug interactions [8].","label":[],"Comments":[]}
{"id":2909,"text":"Newbouldia laevis (family Bignoniaceae) and Cassia abbreviata (family Fabaceae) are medicinal herbal plants that are used in Western and Southern African countries for the treatment and management of many conditions.","label":[[0,39,"Herb name"],[44,79,"Herb name"],[125,153,"Ethnic group"]],"Comments":[]}
{"id":2910,"text":"Newbouldia laevis, also known as the tree of life or boundary tree, is a shrub or small tree that grows in West African countries such as Ghana, Nigeria, and Benin.","label":[[0,17,"Herb name"],[107,119,"Ethnic group"]],"Comments":[]}
{"id":2911,"text":"Local names for this shrub include Faangum in Cameroon, Sasanemasa\/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.","label":[[35,42,"Herb name"],[56,75,"Herb name"],[79,89,"Herb name"],[100,105,"Herb name"],[119,124,"Herb name"]],"Comments":[]}
{"id":2912,"text":"The leaves, stems, and roots are used to treat conditions such as malaria, convulsions, cancer, dyslipidemia, diabetes, hemorrhoids, constipation, peptic ulcer, and cough [9,10].","label":[[4,10,"Herb part"],[12,17,"Herb part"],[23,28,"Herb part"],[66,73,"Pathology"],[75,86,"Pathology"],[88,94,"Pathology"],[96,108,"Pathology"],[110,118,"Pathology"],[120,131,"Pathology"],[133,145,"Pathology"],[147,159,"Pathology"],[165,170,"Pathology"]],"Comments":[]}
{"id":2913,"text":"Cassia abbreviata is a medium-sized tree that grows in most parts of Africa, especially utilized in Southern African countries such as Botswana, South Africa, Uganda, Zambia, and Zimbabwe.","label":[[0,17,"Herb name"],[100,116,"Ethnic group"]],"Comments":[]}
{"id":2914,"text":"Local names for this shrub include Muremberembe in Zimbabwe, Mahemba in Tanzania, and Monepenepe in Botswana and South Africa.","label":[[35,47,"Herb name"],[61,68,"Herb name"],[86,96,"Herb name"]],"Comments":[]}
{"id":2915,"text":"The leaves, stems, and roots are used to treat and\/or manage a number of diseases such as malaria, diabetes, ulcers, headaches, diarrhoea, constipation, and skin diseases [11,12], and are believed to possess anti-HIV activity [13].","label":[[4,10,"Herb part"],[12,17,"Herb part"],[23,28,"Herb part"],[90,97,"Pathology"],[99,107,"Pathology"],[109,115,"Pathology"],[117,126,"Pathology"],[128,137,"Pathology"],[139,151,"Pathology"],[157,170,"Pathology"]],"Comments":[]}
{"id":2916,"text":"Despite the advances made in Western medicine, there are many diseases with no cure and so herbal medicines become the default treatment option.","label":[],"Comments":[]}
{"id":2917,"text":"However, in many cases, herbal medicines are used concurrently with conventional drugs, raising the risk for adverse drug reactions (ADRs) through the alteration of the pharmacokinetic and pharmacodynamics profiles through herb–drug interactions (HDI).","label":[[109,138,"Pathology"]],"Comments":[]}
{"id":2918,"text":"Drug-metabolizing enzymes (DMEs) play a very important role in the metabolism of xenobiotics including therapeutic drugs.","label":[],"Comments":[]}
{"id":2919,"text":"The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].","label":[[4,28,"Target"]],"Comments":[]}
{"id":2920,"text":"The composition of herbal medicines is complicated as they contain a number of different phytochemicals and other substances that give them their therapeutic potential.","label":[],"Comments":[]}
{"id":2921,"text":"Notwithstanding the complicated composition of herbal medicines, most of their metabolism is also dependent on DMEs, including the CYP450 enzymes, which might affect the metabolism of other administered drugs, leading to potentially increased risk of HDI [15,16].","label":[[131,145,"Target"]],"Comments":[]}
{"id":2922,"text":"There are more than 57 cytochrome P-450 genes identified in humans, with the CYP1, CYP2, and CYP3 families contributing to most of the biotransformation of xenobiotics (including therapeutic drugs) [17,18].","label":[[23,39,"Target"],[77,81,"Target"],[83,87,"Target"],[93,97,"Target"]],"Comments":[]}
{"id":2923,"text":"This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.","label":[[86,94,"Extraction process"],[100,117,"Herb name"],[122,139,"Herb name"],[143,149,"Target"],[151,157,"Target"],[163,170,"Target"]],"Comments":[]}
{"id":2924,"text":"CYP1A2 is responsible for the metabolism of drugs including theophylline, caffeine, imipramine, paracetamol, and phenacetin [19].","label":[[0,6,"Target"],[60,72,"Drug"],[84,94,"Drug"],[96,107,"Drug"],[113,123,"Drug"]],"Comments":[]}
{"id":2925,"text":"Among the substrates of CYP2C9 is the anticoagulant warfarin, non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, diclofenac, and naproxen, the hypoglycemic agent tolbutamide, phenytoin, and the angiotensin-II receptor antagonist losartan.","label":[[24,30,"Target"],[38,60,"Drug"],[62,108,"Drug"],[117,126,"Drug"],[128,138,"Drug"],[144,152,"Drug"],[158,188,"Drug"],[190,199,"Drug"],[209,252,"Drug"]],"Comments":[]}
{"id":2926,"text":"CYP2C19 metabolizes a number of commonly used drugs including benzodiazepine diazepam, the proton pump inhibitor omeprazole, propranolol, and the antidepressant amitriptyline [19].","label":[[0,7,"Target"],[62,85,"Drug"],[87,123,"Drug"],[125,136,"Drug"],[146,174,"Drug"]],"Comments":[]}
{"id":2927,"text":"Despite the long-term use of Newbouldia laevis and Cassia abbreviata by several African populations for various ailments, their effects on cytochrome P450 and information on their potential to cause herb-drug interaction (HDI) by inhibition of cytochrome P450 has not been reported.","label":[[29,46,"Herb name"],[51,68,"Herb name"],[80,87,"Target"],[139,154,"Target"],[244,259,"Target"]],"Comments":[]}
{"id":2928,"text":"This study therefore investigated the inhibition profiles of extracts from two medicinal plants, Newbouldia laevis and Cassia abbreviata, on three major CYP450 enzymes, CYP1A2, CYP2C9, and CYP2C19, using recombinant human CYP450 enzymes.","label":[[61,69,"Extraction process"],[97,114,"Herb name"],[119,136,"Herb name"],[153,167,"Target"],[169,175,"Target"],[177,183,"Target"],[189,196,"Target"],[222,236,"Target"]],"Comments":[]}
{"id":2929,"text":"Enzyme kinetic studies were carried out to determine the inhibitory mechanisms of Newbouldia laevis and Cassia abbreviata.","label":[[0,22,"Study"],[82,99,"Herb name"],[104,121,"Herb name"]],"Comments":[]}
{"id":2930,"text":"The potential of these two herbal plants to cause HDI was also evaluated.","label":[],"Comments":[]}
{"id":2931,"text":"Phytofingerprinting was performed in order to evaluate the profile of possible phytocompounds in both Newbouldia laevis and Cassia abbreviata.","label":[[102,119,"Herb name"],[124,141,"Herb name"]],"Comments":[]}
{"id":2932,"text":"The potency of extracts from Newbouldia laevis (NL) and Cassia abbreviata (CA) to cause inhibition of CYP1A2, CYP2C9, and CYP2C19 activity using the rCYP enzymes was investigated.","label":[[15,23,"Extraction process"],[29,51,"Herb name"],[56,78,"Herb name"],[102,108,"Target"],[110,116,"Target"],[122,129,"Target"],[149,161,"Target"]],"Comments":[]}
{"id":2933,"text":"Figure 1 shows the inhibition profiles of NL and CA on CYP1A2, CYP2C9, and CYP2C19.","label":[[42,44,"Herb name"],[49,51,"Herb name"],[55,61,"Target"],[63,69,"Target"],[75,82,"Target"]],"Comments":[]}
{"id":2934,"text":"IC Single point concentrations of the plant extracts at 50 µg\/mL were pre-incubated with or without NADPH and the percentage residual activity compared (Figure 2).","label":[[0,2,"Parameter"],[44,52,"Extraction process"],[100,105,"Target"]],"Comments":[]}
{"id":2935,"text":"Medicinal plant extracts that were pre-incubated with NADPH showed a significant reduction (p < 0.05) in percent activity of CYP1A2, depicting its TDI potency without the possibility of enzyme recovery; this was not observed for CYP2C9 and CYP2C19 enzyme activities.","label":[[16,24,"Extraction process"],[54,59,"Target"],[125,131,"Target"],[229,235,"Target"],[240,247,"Target"]],"Comments":[]}
{"id":2936,"text":"The IC Extracts of NL and CA showed a TDI potency (dashed line) with an IC CYP1A2, CYP2C9, and CYP2C19 activity were inactivated in a reversible and time-dependent manner by extracts of NL and CA.","label":[[4,6,"Parameter"],[7,15,"Extraction process"],[19,21,"Herb name"],[26,28,"Herb name"],[72,74,"Parameter"],[75,81,"Target"],[83,89,"Target"],[95,102,"Target"],[174,182,"Extraction process"],[186,188,"Herb name"],[193,195,"Herb name"]],"Comments":[]}
{"id":2937,"text":"Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.","label":[],"Comments":[]}
{"id":2938,"text":"The gradient parameters were adjusted by systematically changing the percentage of solvents to be able to determine as many compounds as possible.","label":[],"Comments":[]}
{"id":2939,"text":"The chromatograms obtained (Figure 8) showed the retention times of the various compounds that were found in the extracts.","label":[[113,121,"Extraction process"]],"Comments":[]}
{"id":2940,"text":"Using fragmentation data, and available databases, possible compounds that might be found in the extracts were proposed for CA (Table 1) and NL (Table 2).","label":[[97,105,"Extraction process"],[124,126,"Herb name"],[141,143,"Herb name"]],"Comments":[]}
{"id":2941,"text":"Selected structures of these polyphenols are shown in Figure 9 and Figure 10 for Cassia abbreviata and Newbouldia laevis respectively.","label":[[29,40,"Herb name"],[81,98,"Herb name"],[103,120,"Herb name"]],"Comments":[]}
{"id":2942,"text":"It is becoming a common occurrence for in vitro data from HDI studies to be used to predict in vivo HDI risk [21,22,23].","label":[[39,47,"Study"]],"Comments":[]}
{"id":2943,"text":"Therefore, in this study, the putative GIT concentration that serves as the inhibitor concentration was calculated as shown in Table 3.","label":[],"Comments":[]}
{"id":2944,"text":"Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material\/weight of original starting material) to give the soluble extract available in the GIT tract.","label":[[128,136,"Extraction process"],[152,167,"Parameter"],[178,204,"Parameter"],[323,338,"Extraction process"]],"Comments":[]}
{"id":2945,"text":"With this knowledge, differential bioavailable concentration was calculated as seen in Table 3.","label":[[34,60,"Parameter"]],"Comments":[]}
{"id":2946,"text":"The IC The therapeutic efficacy of medicinal herbal plants is well acknowledged in both developed and developing countries.","label":[[4,6,"Parameter"]],"Comments":[]}
{"id":2947,"text":"Medicinal plants from different countries mostly lack valid documentation on their safety, efficacy, manufacturing standards, and quality control.","label":[],"Comments":[]}
{"id":2948,"text":"Given the varied amounts of compounds found in medicinal herbal plants, standardization parameters and development of marker profiles of commonly used medicinal plants are very important for maintaining the quality of herbal remedies and also provide knowledge on the optimal concentrations of the various bio-constituents [25,26].","label":[],"Comments":[]}
{"id":2949,"text":"Despite being natural, medicinal plant extracts are not free from risks and interactions with other drugs and herbs, which may lead to significant public health consequences including the possibility of being fatal [5,6].","label":[[39,47,"Extraction process"]],"Comments":[]}
{"id":2950,"text":"Traditionally, whole plants or mixtures of medicinal plants are used rather than isolated compounds from these plants.","label":[],"Comments":[]}
{"id":2951,"text":"Evidence indicates that crude plant extracts often have greater in vitro and\/or in vivo therapeutic activity than isolated constituents at an equivalent dose.","label":[[24,44,"Extraction process"]],"Comments":[]}
{"id":2952,"text":"The aim of this study therefore was to evaluate the CYP450 inhibition activities of Newbouldia laevis and Cassia abbreviata extracts commonly used in West and Southern Africa for the treatment and\/or management of common communicable and non-communicable diseases.","label":[[52,58,"Target"],[84,101,"Herb name"],[106,123,"Herb name"],[124,132,"Extraction process"]],"Comments":[]}
{"id":2953,"text":"It was observed that extracts from these two plants had differential inhibitory effects on CYP1A2, 2C9, and 2C19.","label":[[21,29,"Extraction process"],[91,112,"Target"]],"Comments":[]}
{"id":2954,"text":"This could be used for initial assessment of the potential risk of HDI, which would bring awareness and educate the public and\/or patients on the dangers of co-use of herbal medicinal remedies and conventional medications.","label":[],"Comments":[]}
{"id":2955,"text":"Drug interactions can result in clinical fatalities; thus, in the drug discovery process, guidelines and opinions have been published by the FDA, EMA, and pharmaceutical industries [27,28] for the conducting of drug–drug interaction (DDI) studies to help target drugs that are likely to cause interactions at the early stages so that such entities can be either discontinued or modified before further processing.","label":[[211,246,"Study"]],"Comments":[]}
{"id":2956,"text":"The potential interactions of herbal remedies with prescribed or over-the-counter drugs has been a major safety concern for clinicians and public health practitioners, as such interactions are difficult to predict and also, generally, there is a lack of available information on the composition of herbs and their pharmacological actions [29].","label":[],"Comments":[]}
{"id":2957,"text":"With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.","label":[[163,174,"Study"]],"Comments":[]}
{"id":2958,"text":"This is helpful with labelling purposes for commercially available herbal products and also to caution patients from combining herbal remedies with known conventional medications [30].","label":[],"Comments":[]}
{"id":2959,"text":"There is limited information currently available regarding the potential of Newbouldia laevis and Cassia abbreviata to interact with clinically prescribed drugs.","label":[[76,93,"Herb name"],[98,115,"Herb name"]],"Comments":[]}
{"id":2960,"text":"This is a safety issue as these herbal plant remedies are commonly used by certain populations.","label":[],"Comments":[]}
{"id":2961,"text":"This study therefore looked at the drug interaction potential of N. laevis and C. abbreviata extracts on three major cytochrome P450 enzymes, CYP1A2, CYP2C9, and CYP2C19.","label":[[65,74,"Herb name"],[79,92,"Herb name"],[93,101,"Extraction process"],[117,140,"Target"],[142,148,"Target"],[150,156,"Target"],[162,169,"Target"]],"Comments":[]}
{"id":2962,"text":"Typically, new chemical entities (NCE) are assessed for their potential to cause CYP-mediated drug interaction based on a single concentration screening and later a detailed classification involving IC Crude N. laevis and C. abbreviata extracts were used in this study to mimic the way patients take these herbal remedies and also the mode of extraction simulated to show the indigenous mode of extraction.","label":[[199,201,"Parameter"],[202,244,"Extraction process"],[208,217,"Herb name"],[222,235,"Herb name"]],"Comments":[]}
{"id":2963,"text":"Newbouldia laevis extract showed a strong reversible inhibitory effect on CYP1A2 and CYP2C9 enzyme activities whilst exhibiting a moderate reversible inhibition on CYP2C19.","label":[[0,17,"Herb name"],[18,25,"Extraction process"],[74,80,"Target"],[85,91,"Target"],[164,171,"Target"]],"Comments":[]}
{"id":2964,"text":"Cassia abbreviata extract showed a strong reversible inhibitory effect on CYP1A2, CYP2C9, and CYP2C19 enzyme activities.","label":[[0,17,"Herb name"],[18,25,"Extraction process"],[74,80,"Target"],[82,88,"Target"],[94,101,"Target"]],"Comments":[]}
{"id":2965,"text":"The implication is that there is a possibility of enzyme recovery should the herbal extracts inactivate these CYPs.","label":[[84,92,"Extraction process"],[110,114,"Target"]],"Comments":[]}
{"id":2966,"text":"Time-dependent inhibition of CYP450 enzymes that is caused by NCEs is of great concern because such compounds can cause clinically relevant DDI or HDI [31].","label":[[29,43,"Target"]],"Comments":[]}
{"id":2967,"text":"The TDI of a CYP enzyme refers to the change in inhibition potency of a NCE as a result of a dosing period that leads to formation of inhibitory metabolites and mechanism-based inhibition [32].","label":[[4,7,"Parameter"],[13,23,"Target"]],"Comments":[]}
{"id":2968,"text":"The use of the IC The differential reversible and irreversible inhibition of CYP1A2, CYP2C9, and CYP2C19 enzymes by Newbouldia laevis and Cassia abbreviata extracts implies that patients who are on prescribed drugs that have narrow therapeutic ranges (for example, theophylline, caffeine, imipramine, paracetamol, phenacetin-CYP1A2, warfarin, non-steroidal anti-inflammatory drugs (NSAIDs), tolbutamide, phenytoin, losartan-CYP2C9, diazepam, omeprazole, propranolol, amitriptyline-CYP2C19, or over-the-counter drugs that are metabolized by similar CYP450 enzymes) stand a risk of having HDI, which can lead to clinical consequences.","label":[[15,17,"Parameter"],[77,83,"Target"],[85,91,"Target"],[97,104,"Target"],[116,133,"Herb name"],[138,155,"Herb name"],[156,164,"Extraction process"],[265,277,"Drug"],[289,299,"Drug"],[301,312,"Drug"],[314,324,"Drug"],[325,331,"Target"],[333,341,"Drug"],[343,389,"Drug"],[391,402,"Drug"],[404,413,"Drug"],[415,423,"Drug"],[424,430,"Target"],[432,440,"Drug"],[442,452,"Drug"],[454,465,"Drug"],[467,480,"Drug"],[481,488,"Target"],[548,562,"Target"]],"Comments":[]}
{"id":2969,"text":"The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.","label":[],"Comments":[]}
{"id":2970,"text":"Single point screening for the effects of pre-incubation with NADPH was performed on CYP1A2, CYP2C9, and CYP2C19.","label":[[62,67,"Target"],[85,91,"Target"],[93,99,"Target"],[105,112,"Target"]],"Comments":[]}
{"id":2971,"text":"Data showed significant effects of pre-incubation of Newbouldia laevis extracts on CYP1A2 enzyme activity but not CYP2C9 and CYP2C19 enzyme activities.","label":[[53,70,"Herb name"],[71,79,"Extraction process"],[83,89,"Target"],[114,120,"Target"],[125,132,"Target"]],"Comments":[]}
{"id":2972,"text":"Cassia abbreviata extracts, however, exhibited significant effects on CYP1A2 and CYP2C19 enzyme activities after pre-incubation with NADPH but not CYP2C9 enzyme activity.","label":[[0,17,"Herb name"],[18,26,"Extraction process"],[70,76,"Target"],[81,88,"Target"],[133,138,"Target"],[147,153,"Target"]],"Comments":[]}
{"id":2973,"text":"These results combined with the TDI potencies imply that these herbs’ inhibitory effects may either be increased or reduced after pre-incubation.","label":[],"Comments":[]}
{"id":2974,"text":"The weakening inhibition potency could be due to recovery of enzyme activity since the inhibition potency of the herbs weakens with time regardless of the concentration applied, whilst the increase in inhibitory potency could be due to the interaction of the herb with CYP450 enzymes during pre-incubation.","label":[[269,283,"Target"]],"Comments":[]}
{"id":2975,"text":"Following the inactivation of CYP1A2, CYP2C9, and CYP2C19, the inactivation parameters were determined.","label":[[30,36,"Target"],[38,44,"Target"],[50,57,"Target"]],"Comments":[]}
{"id":2976,"text":"The kinetic parameters for the inactivation of CYP1A2 by Newbouldia laevis and Cassia abbreviata extracts were: K Herbal medicines consist of multi-phytochemical constituents with different physicochemical properties.","label":[[47,53,"Target"],[57,74,"Herb name"],[79,96,"Herb name"],[97,105,"Extraction process"]],"Comments":[]}
{"id":2977,"text":"The risk of HDI of orally administered herbal remedies depends on the bioavailable fraction of the phyto-constituents [34], which may or may not permeate through membrane barriers.","label":[],"Comments":[]}
{"id":2978,"text":"Due to the multi-phyto nature of herbals, their bio-availabilities are variable depending on the constituents [24].","label":[[48,66,"Parameter"]],"Comments":[]}
{"id":2979,"text":"Prediction of in vivo HDI using in vitro results [21,23,35,36] gives preliminary information that can caution patients to be wary of combination therapies of herbals with conventional medications and also for pharmaceutical companies and researchers to get baseline information guiding further investigation.","label":[[32,40,"Study"]],"Comments":[]}
{"id":2980,"text":"For herbal extracts that are already in use, HDI studies allow assessment of risk, helping with the design of in vivo HDI studies and revision of product labels to highlight the risk of co-use of these herbs with conventional medication, as in the case of Saint John′s Wort and the protease inhibitor indinavir [37].","label":[[11,19,"Extraction process"],[45,56,"Study"],[110,129,"Study"],[256,273,"Herb name"],[279,310,"Drug"]],"Comments":[]}
{"id":2981,"text":"This study assessed the risk of HDI on CYP1A2, CYP2C9, and CY2C19 activities and predicted these herbals can cause HDIs in vivo to a significant extent, with the assumption that at least one phyto-constituent is absorbed to cause HDI.","label":[[39,45,"Drug"],[47,53,"Drug"],[59,65,"Drug"]],"Comments":[]}
{"id":2982,"text":"Profiling of herbal extracts for the phyto-constituents is a critical step in elucidating the possible mechanisms for HDI potential.","label":[[20,28,"Extraction process"]],"Comments":[]}
{"id":2983,"text":"Based on the UPLC-MS data obtained, the crude extracts of Newbouldia laevis and Cassia abbreviata are composed of several different phenolic compounds.","label":[[40,54,"Extraction process"],[58,75,"Herb name"],[80,97,"Herb name"],[132,150,"Herb name"]],"Comments":[]}
{"id":2984,"text":"The UPLC-MS profiles indicated the presence of at least 10 polyphenolic candidates including catechins and potent antioxidant flavonoids, which likely give these herbs their therapeutic effects.","label":[[59,82,"Herb name"],[93,102,"Herb name"],[114,136,"Herb name"]],"Comments":[]}
{"id":2985,"text":"Epidemiological studies of polyphenols suggest that consumption of polyphenol-rich herbs and beverages may contribute to the prevention of diseases including cancers, cardiovascular diseases, osteoporosis, neurodegenerative diseases, and diabetes [38,39].","label":[[0,23,"Study"],[27,38,"Herb name"],[67,88,"Herb name"],[158,165,"Pathology"],[167,190,"Pathology"],[192,204,"Pathology"],[206,232,"Pathology"],[238,246,"Pathology"]],"Comments":[]}
{"id":2986,"text":"However, some of these polyphenols are known to inhibit CYP450 [40,41,42,43].","label":[[23,34,"Herb name"],[56,62,"Target"]],"Comments":[]}
{"id":2987,"text":"It is therefore possible that the interactions observed in this study may be related to some of the constituents that are in these herbs.","label":[],"Comments":[]}
{"id":2988,"text":"Inhibition and kinetic reactions were carried out in Black costar 96-well plates bought from Thermo Fischer Scientific (Pittsburgh, PA, USA).","label":[],"Comments":[]}
{"id":2989,"text":"α-naphthoflavone, furafylline, sulphaphenazole, and miconazole were purchased from Sigma-Aldrich (St. Louis, MO, USA).","label":[[18,29,"Drug"],[31,46,"Drug"],[52,62,"Drug"]],"Comments":[]}
{"id":2990,"text":"Vivid The leaves of Newbouldia laevis (UCC\/BS\/689) and Cassia abbreviata (UB\/B\/151) were obtained with the assistance of traditional herbal practitioners and authenticated by a botanist from the University of Cape Coast herbarium.","label":[[10,16,"Herb part"],[20,37,"Herb name"],[55,72,"Herb name"]],"Comments":[]}
{"id":2991,"text":"Voucher specimens were kept at the University of Cape Coast herbarium.","label":[],"Comments":[]}
{"id":2992,"text":"The plant material was air-dried at room temperature and ground into a fine powder.","label":[],"Comments":[]}
{"id":2993,"text":"Extraction was performed using water to mimic the indigenous mode of extraction.","label":[],"Comments":[]}
{"id":2994,"text":"Powdered plant material (10 g) was added to 100 mL of distilled water, heated for one hour at 60 °C, and allowed to extract for 72 h with 24 h decanting of supernatant and refilling with the same volume of distilled water on solid residue.","label":[],"Comments":[]}
{"id":2995,"text":"Supernatants were pooled, centrifuged (14,000× g, 10 min), and filtered using a filter paper (8 µm, Whatman International LTD, Maidstone, UK).","label":[],"Comments":[]}
{"id":2996,"text":"Filtrates were freeze-dried using a Virtis sentry freeze dryer (the Virtis Company, NC, Gardiner, NY, USA) and the dried powder stored in airtight containers at –20°C until subsequent experiments.","label":[],"Comments":[]}
{"id":2997,"text":"The determination of reversible inhibition was carried out as reported in a previous study with slight modification [23].","label":[],"Comments":[]}
{"id":2998,"text":"An initial study of two-point screening indicated that 100 µg\/mL exhibited the maximum inhibitory effect on CYP1A2, CYP2C9, and CY2C19.","label":[[108,114,"Target"],[116,122,"Target"],[128,134,"Target"]],"Comments":[]}
{"id":2999,"text":"Reconstitution of extracts in subsequent experiments were performed with 100 µg\/mL concentration as the highest concentration.","label":[[18,26,"Extraction process"]],"Comments":[]}
{"id":3000,"text":"Briefly, serial dilutions (1:3) of the medicinal plant extracts from a concentration of 100 µg\/mL were pre-incubated with a mixture of CYP 450 BACULOSOME The procedure followed was similar to that used for the screening of CYP450 inhibition with a slight modification that included employing the curve shift method by Berry and Zhao [20].","label":[[55,63,"Extraction process"],[135,142,"Target"],[223,229,"Target"]],"Comments":[]}
{"id":3001,"text":"Plant extracts with a starting concentration of 100 µg\/mL were serially diluted (1:3) in black costar 96-well plates.","label":[[6,14,"Extraction process"]],"Comments":[]}
{"id":3002,"text":"The black costar plates were divided into two halves.","label":[],"Comments":[]}
{"id":3003,"text":"One half contained a reaction mixture made of BACULOSOME The method used is a slight modification of the CYP450 inhibition and TDI determinations according to the method of Krippendorff et al.","label":[[105,111,"Target"]],"Comments":[]}
{"id":3004,"text":"[44].","label":[],"Comments":[]}
{"id":3005,"text":"Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm × 100 mm, 1.7 µm particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.","label":[[33,41,"Extraction process"],[90,94,"Target"],[136,144,"Extraction process"]],"Comments":[]}
{"id":3006,"text":"Gradient elution was performed at a flow rate of 0.1 mL\/min throughout at injection volumes of 10 µL.","label":[],"Comments":[]}
{"id":3007,"text":"Gradient parameters were adjusted by systematically changing the percentage organic modifier at initial conditions, and\/or the isocratic hold period at initial conditions, and\/or gradient steepness.","label":[],"Comments":[]}
{"id":3008,"text":"Electrospray mass spectra data were recorded on a negative ionization mode for a mass range m\/z 100 to m\/z 1500 at a collision energy of 50 V. Relative quantification of some constituents of the extracts was performed as stated previously [23].","label":[],"Comments":[]}
{"id":3009,"text":"Standards of epicatechin, catechin, chlorogenic acid, caffeic acid, and p-coumaric acid were used to generate calibration curves and quantities derived from the calibration curves.","label":[[13,24,"Herb name"],[26,34,"Herb name"],[36,52,"Herb name"],[54,66,"Herb name"],[72,87,"Herb name"]],"Comments":[]}
{"id":3010,"text":"Calibration curve ranges for each reference compound ranged from 0.1 to 100 µg\/mL.","label":[],"Comments":[]}
{"id":3011,"text":"Data generated were exported into an Excel spreadsheet and the amount of metabolite formed at the various concentrations relative to the control (residual activity) was calculated using the equation below:  Percentage residual activity was plotted against the log-transformed concentrations of the extracts and positive inhibitors.","label":[[298,306,"Extraction process"]],"Comments":[]}
{"id":3012,"text":"Non-linear regression analysis was used for the sigmoid curve fitting and IC The natural logarithm of the percentage remaining activity was plotted against the pre-incubation times at each extract concentration to obtain K All values are expressed as Mean ± SEM.","label":[[74,76,"Parameter"],[189,196,"Extraction process"]],"Comments":[]}
{"id":3013,"text":"Comparisons for significance were performed using unpaired t-test with p < 0.05 considered statistically significant.","label":[],"Comments":[]}
{"id":3014,"text":"Most patients in developed and developing countries consume herbal medicines for reasons already elucidated in addition to conventional medicines.","label":[],"Comments":[]}
{"id":3015,"text":"This study has evaluated the inhibitory potencies of Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.","label":[[53,70,"Herb name"],[75,92,"Herb name"],[96,102,"Target"],[104,110,"Target"],[116,123,"Target"]],"Comments":[]}
{"id":3016,"text":"It is observed that these two herbs caused differential inhibition of the CYPs and are likely to cause HDI.","label":[[74,78,"Target"]],"Comments":[]}
{"id":3017,"text":"This study gives information on two herbs that have been used for decades and this may be used to caution patients to desist from combining them with other conventional medications.","label":[],"Comments":[]}
{"id":3018,"text":"Research reported in this publication was supported by the National Research Foundation (NRF) under an Indigenous Knowledge Systems Research Grant.","label":[],"Comments":[]}
{"id":3019,"text":"The views and opinions expressed are not those of the NRF but of the authors of the material published.","label":[],"Comments":[]}
{"id":3020,"text":"NET is funded by an NRF grant-holder linked bursary.","label":[],"Comments":[]}
{"id":3021,"text":"Sample Availability: Samples of the compounds are not available from the authors.","label":[],"Comments":[]}
{"id":3022,"text":"Collet Dandara, Dee Blackhurst, Ambroise Wonkam, and Nicholas Ekow Thomford, contributed to the design of the study.","label":[],"Comments":[]}
{"id":3023,"text":"All authors have materially participated in the manuscript preparation.","label":[],"Comments":[]}
{"id":3024,"text":"Nicholas Ekow Thomford performed the laboratory and data analysis.","label":[],"Comments":[]}
{"id":3025,"text":"Nicholas Ekow Thomford and Collet Dandara wrote the draft manuscript and interpretation of data.","label":[],"Comments":[]}
{"id":3026,"text":"Dennis Chopera, Dee Blackhurst, Ambroise Wonkam, and Kevin Dzobo commented.","label":[],"Comments":[]}
{"id":3027,"text":"All authors reviewed the final manuscript.","label":[],"Comments":[]}
{"id":3028,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
{"id":3029,"text":"Inhibition profiles (IC Inhibitory effects of 50 µg\/mL concentration of Newbouldia laevis (NL) and Cassia abbreviata (CA) after pre-incubation with NADPH.","label":[[21,23,"Parameter"],[72,94,"Herb name"],[99,121,"Herb name"],[148,153,"Target"]],"Comments":[]}
{"id":3030,"text":"(A): CYP1A1; (B): CYP2C9 and (C): CYP2C19, * Significant p value.","label":[[5,11,"Target"],[18,24,"Target"],[34,41,"Target"]],"Comments":[]}
{"id":3031,"text":"IC Time-dependent inhibition (TDI) classification of medicinal plant extracts on CYP1A2, CYP2C9, and CYP219 activity based on the IC Double reciprocal plots of K Double reciprocal plots of K Double reciprocal plots of K Profiles of crude extracts of Cassia abbreviata (CA) and Newbouldia laevis (NL) after UPLC-MS analysis.","label":[[0,34,"Parameter"],[69,77,"Extraction process"],[81,87,"Target"],[89,95,"Target"],[101,107,"Target"],[130,132,"Parameter"],[232,246,"Extraction process"],[250,272,"Herb name"],[277,299,"Herb name"]],"Comments":[]}
{"id":3032,"text":"(A,B) represent chromatograms for CA and NL respectively.","label":[[34,36,"Herb name"],[41,43,"Herb name"]],"Comments":[]}
{"id":3033,"text":"Structures of some of the proposed compounds identified from crude herbal extract of Cassia abbreviata: (A) Cassiaflavan-(4α→6) epiafzelechin; (B) Cassiaflavan-(4β→8) epiafzelechin; (C) Epicatechin-(4β→8) epiafzelechin.","label":[[61,81,"Extraction process"],[85,102,"Herb name"],[108,141,"Herb name"],[147,180,"Herb name"],[186,218,"Herb name"]],"Comments":[]}
{"id":3034,"text":"Structures of some of the proposed compounds identified from crude herbal extracts of Newbouldia laevis: (A) Apigenin; (B) Newbouldiside A; (C) Luteoside B.","label":[[61,82,"Extraction process"],[86,103,"Herb name"],[109,117,"Herb name"],[123,138,"Herb name"],[144,155,"Herb name"]],"Comments":[]}
{"id":3035,"text":"Compounds identified in extracts of Cassia abbreviata (CA).","label":[[24,32,"Extraction process"],[36,58,"Herb name"]],"Comments":[]}
{"id":3036,"text":"Compounds identified in extract of Newbouldia laevis (NL).","label":[[24,31,"Extraction process"],[35,57,"Herb name"]],"Comments":[]}
{"id":3037,"text":"Calculation of herbal medicine concentration in the gut.","label":[],"Comments":[]}
{"id":3038,"text":"Note: GIT, Gastrointestinal tract, Putative GIT concentration = dose\/ estimated gut fluid volume of 250 mL, estimated bioavailable concentration = (% yield × putative GIT concentration)\/100.","label":[[118,144,"Parameter"]],"Comments":[]}
{"id":3039,"text":"In vivo prediction of HDI from in vitro data for CYP1A2, CYP2C9, and CYP2C19.","label":[[31,39,"Study"],[49,55,"Target"],[57,63,"Target"],[69,76,"Target"]],"Comments":[]}
{"id":3040,"text":"Note: HDI, herb-drug interaction, inhibitor concentration = estimated bioavailable concentration (µg\/mL), * the likelihood of a clinically relevant interaction when these herbal extracts are taken is based on the assumption that the % yield serves as the bioavailable fraction, which was used in estimating the bioavailable concentration in the gut and also if there is complete absorption.","label":[[34,57,"Parameter"],[60,96,"Parameter"],[178,186,"Extraction process"],[311,337,"Parameter"]],"Comments":[]}
{"id":3041,"text":"Experimental conditions involved in fluorogenic assay.","label":[],"Comments":[]}
